Serenic | |
---|---|
Drug class | |
Class identifiers | |
Synonyms | Anti-aggressive drug; Anti-aggressive agent; Anti-aggressive medication; Antiaggressive drug; Antiaggressive agent; Antiaggressive medication |
Use | To reduce aggression and anger |
Legal status | |
In Wikidata |
A serenic, or anti-aggressive drug, is a type of drug which reduces the capacity for aggression. [1]
The recreational drug MDMA ("ecstasy") and a variety of related drugs have been described as empathogen-entactogens , or simply as entactogens. [2] These agents possess serenic and empathy-increasing properties in addition to their euphoriant effects, and have been associated with increased sociability, friendliness, and feelings of closeness to others as well as emotional empathy and prosocial behavior. [3] [4] The entactogenic effects of these drugs are thought to be related to their ability to temporarily increase the levels of certain brain chemicals, including serotonin, [5] dopamine, and, particularly, oxytocin. [3] [6] [7]
Certain other serotonergic drugs, such as 5-HT1A receptor agonists, also increase oxytocin levels and may possess serenic properties as well. [8] The phenylpiperazine mixed 5-HT1A and 5-HT1B receptor agonists eltoprazine, fluprazine, and batoprazine have been described based on animal research as serenics. [9] The selective 5-HT1A biased full agonist F-15,599 (NLX-101) has shown antiaggressive effects in rodents as well. [10]
The serotonin 5-HT2C receptor agonist lorcaserin has been found to reduce impulsive aggression in people with intermittent explosive disorder (IED). [11] [12] [13] [14] Serotonin 5-HT2C receptor agonists have also been found to produce antiaggressive effects in rodents. [11]
The serotonergic psychedelics DOB and DOI, which act as serotonin 5-HT2 receptor agonists, show antiaggressive effects in rodents. [11] [15] [16] [17] However, DOI has also been found to have pro-aggressive effects. [11] In older literature, other psychedelics, including LSD, psilocin, dimethyltryptamine (DMT), and mescaline, have been found to reduce aggression in monkeys, but have also been found to increase aggression in animals in other contexts. [18] Serotonin 5-HT2A receptor antagonists have been found to reduce aggression in animals. [11] Atypical antipsychotics, which act in part as serotonin 5-HT2A receptor antagonists, have antiaggressive effects in humans. [11] The selective serotonin reuptake inhibitors (SSRIs) sertraline, fluvoxamine, and fluoxetine inhibited aggression in rodents, whereas the SSRIs citalopram and paroxetine were ineffective. [19] [20]
Antipsychotics, which are dopamine D2 receptor antagonists, are well-known as reducing aggression in humans and have been clinically employed for this purpose. [21] Molindone is under development for the treatment of impulsive aggression in children and adolescents with attention deficit hyperactivity disorder (ADHD). [22] [23]
Beta blockers, or β-adrenergic receptor antagonists, have been used to treat aggression and agitation. [24] Beta blockers that have been used for such purposes include propranolol, pindolol, and nadolol. [24]
Nicotinic acetylcholine receptors within the CNS, specifically α7 homopentameric receptors, are implicated in the regulation of aggression. The serenic effect of nicotine is well documented both in laboratory animals and humans, and, conversely, nicotinic receptor antagonists and nicotine withdrawal are associated with irritability and aggression. [25] [26] [27] Additionally, nicotinic receptors are required for rabies virus entry into a neuron, and the dysfunction of these neurons is implicated in the rabies-associated aggression. [28]
Cannabinoids like nabilone have been studied and reported effective for management of severe aggression in people with profound autism and other intellectual and developmental disabilities. [29]
Agonists and antagonists of the receptors for the endogenous hormones oxytocin and vasopressin, respectively, have been shown to decrease aggressive behavior in scientific research, implicating them in the normal regulation of pathways involving aggressive behavior in the brain. [30] [31] Certain neurosteroids, such as allopregnanolone, also appear to play a role in the regulation of aggression, including, notably, sexually-dimorphic aggressive behavior. [32] The sex hormones testosterone and estradiol regulate aggression as well. [33] [34] [35]
There are some pharmacological data indicating a link between aggressive behavior and 5-HT2A receptor activity. In animals, 5-HT2A agonists, such as DOI, reduced aggressive behavior in flies, amphibians, mice and rats [34]. However, accumulated data also revealed a pro-aggressive effect of the 5-HT2A agonist DOI [119,120], whereas 5-HT2A antagonists effectively suppressed aggressive behavior [119,121,122]. In humans, a number of atypical antipsychotics, which act as antagonists of 5-HT2A receptors, had antiaggressive effects in clinical trials reviewed by Comai and co-authors [123]. [...] There are a few currently available data in support of the antiaggressive role of 5-HT2C receptors: (1) the activation of 5-HT2C receptors enhanced the display of defeat submissive and defensive behavior in golden hamsters [172]. (2) 5-HT2C receptor agonist/alpha 2 receptor antagonist S32212 suppressed aggressive behavior in mice [173]. (3) Mice expressing only the VGV isoform of 5-HT2C receptors displayed a high level of conspecific aggression [174]. (4) The association between Htr2c gene polymorphism and criminal behavior in humans was demonstrated [175]. (5) Recently, a novel 5-HT2C agonist, lorcaserin, has been demonstrated to have antiaggressive properties in human subjects with impulsive aggressive behavior. Lorcaserin attenuated provoked, but not unprovoked, aggression in impulsively aggressive individuals indicating that 5-HT2C receptor may be a putative target for the treatment of impulsive aggressive behavior in human subjects [176].
Based on evidence from a recent pilot study, lorcaserin, a selective 5-HT2c agonist, was found to have anti-aggressive effects in humans with high levels of impulsive aggression like in those diagnosed with IED.
Another 5HT2A receptor partial agonist, DOB, has a marginally higher affinity for the 5HT2A receptor (in its low affinity state) than DOI (Roth et al. 1997), and in the water competition (WC) test it has been shown to block defensive aggression in rats. Interestingly, DOI also reduced the number of offensive aggressive behaviors (i.e., attacks, greater latency to first attack, shorter attack duration) in the same animals that exhibited DOI-induced reductions in defensive behaviors during the WC test (Muehlenkamp et al. 1995).